Mauna Kea Technologies: Review of recent developments

Mauna Kea Technologies, a specialist in confocal laser endomicroscopy, shared its recent progress, particularly in the study of food intolerances. Since the UEG Week 2024 conference, the company has recorded significant interest from professionals. The launch of the CellTolerance program has been official in several clinics in France, with studies already underway at Stanford University in the United States.

The company aims to consolidate its finances to support its projects. Despite the volatility of its stock market share, it expects to meet its financial needs until the first quarter of 2025. Discussions are underway with partners to extend this period.

With 24 years of experience, Mauna Kea has demonstrated resilience in the face of financial challenges. Management is committed to keeping its investors informed of the progress of its projects.